Icon Advisers’s Pacira BioSciences PCRX Stock Holding History

Icon Advisers’s Portfolio PCRX Stock Details PCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q2	–	Sell	-18,700	Closed	-$853K	–	412
2017 Q1	$853K	Buy	+18,700	New	+$808K	0.06%	292
2016 Q4	–	Sell	-23,000	Closed	-$787K	–	439
2016 Q3	$787K	Buy	+23,000	New	+$901K	0.05%	328
2015 Q2	–	Sell	-10,400	Closed	-$924K	–	368
2015 Q1	$924K	Buy	+10,400	New	+$1.06M	0.05%	237

Other funds holding PCRX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

HealthCor Management New York $109M AUM 10.64% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return

DCM

Daruma Capital Management New York $879M AUM 2.11% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

Icon Advisers's PCRX Position: Q2 2017 in Review

Icon Advisers sold out of Pacira BioSciences (PCRX) in Q2 2017, closing a stake of 18,700 shares — an estimated $853K sold.

Icon Advisers first reported a position in PCRX in Q1 2015 and held it in 3 quarters. The position peaked at $924K in Q1 2015. 196 funds tracked by Wall St. Rank hold PCRX as of Q2 2017.

Icon Advisers reported no remaining Pacira BioSciences position as of Q2 2017 after selling out during the quarter.
Icon Advisers sold 18,700 Pacira BioSciences shares in Q2 2017, an estimated $853K.
Icon Advisers first reported a position in Pacira BioSciences in Q1 2015 and held it in 3 quarters.
Icon Advisers's Pacira BioSciences position peaked at $924K in Q1 2015.
196 funds tracked by Wall St. Rank held Pacira BioSciences as of Q2 2017.

Based on Icon Advisers's 13F filing for Q2 2017, filed 10 Aug 2017.